SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Successfully reported this slideshow.
Activate your 30 day free trial to unlock unlimited reading.
Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?
Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?
1.
Dr. Diego A. Rodríguez MD, PhD.
Pulmonary Hypertension Unit and Pulmonary Embolism Response Team,
Pulmonology Department, Hospital del Mar, Barcelona.
darodriguez@psmar.cat
Novel biomarkers in pulmonary hypertension:
therapeutic implications nowadays?
2.
SCHEMATIC DIAGRAM SHOWING DIFFERENT GROUPS OF BIOMARKERS
FOR PULMONARY HYPERTENSION
3.
BIOMARKERS FOR A SAME DISEASE (?)
Eur Respir J 2012; 40: 596–603
Eur Respir J. 2019 Jan 24;53(1).
4.
COMPARISON AMONG MAIN FEATURES OF BIOMARKERS
THAT MAY INFLUENCE THEIR USE IN CLINICAL PRACTICE
5.
BIOMARKER CORRELATIONS WITH CLINICAL ENDPOINTS
AND PROGNOSIS IN PULMONARY HYPERTENSION
Biomarker signatures that might predict
favorable responses to therapies.
0
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
6.
TREATMENT-RELATED BIOMARKER CHANGES
IN PULMONARY HYPERTENSION
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
7.
CLINICAL TRIALS EVALUATING NT-PROBNP AS A BIOMARKER FOR
PULMONARY ARTERIAL HYPERTENSION COMBINATION THERAPY
Am J Cardiol 2017;120:S89–S95
8.
BIOMARKERS (No, Thanks)
Eur Respir J. 2019 Jan 24;53(1)
9.
RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION
2015 ESC/ERS Guidelines
10.
Risk assessment, prognosis and guideline implementation in
pulmonary arterial hypertension
Eur Respir J. 2017 Aug 3;50(2)
Kidney Function
Obesity
Age
11.
THE BEST BIOMARKER !!!! (2019 “up-date”)
Eur Respir J 2018; 52: 1800497
12.
THE BEST BIOMARKER !!!! (2019 “up-date”)
Advances in Pulmonary Hypertension Volume 16, Number 3; 2018
13.
DYSPNEA, THE GREAT UNKNOWN ...
Eur Respir J. 2019 Jan 24;53(1).
14.
Vasoregulatory mediators and/or biomarkers relevant to current pulmonary
arterial hypertension (PAH) therapy, and their interactions.
Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
Endothelial cells
vascular smooth muscle cells
Endogenous mediators Enzymes or other protein targets
Mediator-relevant drugs
(stimulatory)
Mediator-relevant drugs
(inhibitory])
15.
CONCLUSIONS
• There is no single biomarker in PH that shows superiority in
predicting patient response.
• An integrative approach is necessary, using a combination of
biomarkers along with other clinical and paraclinical tests like
NYHA functional class and echocardiography.
• The identification of novel biomarker is urgently needed to help
optimize and individualize therapy.
16.
Dr. Diego A. Rodríguez MD, PhD.
Pulmonary Hypertension Unit and Pulmonary Embolism Response Team,
Pulmonology Department, Hospital del Mar, Barcelona.
darodriguez@psmar.cat
Novel biomarkers in pulmonary hypertension:
therapeutic implications nowadays?
0 likes
Be the first to like this
Views
Total views
65
On SlideShare
0
From Embeds
0
Number of Embeds
0
You have now unlocked unlimited access to 20M+ documents!
Unlimited Reading
Learn faster and smarter from top experts
Unlimited Downloading
Download to take your learnings offline and on the go
You also get free access to Scribd!
Instant access to millions of ebooks, audiobooks, magazines, podcasts and more.
Read and listen offline with any device.
Free access to premium services like Tuneln, Mubi and more.